ClinicalTrials.gg
Active, not recruitingNCT05751668Updated Oct 19, 2026

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel

A Phase 2 interventional study of Paclitaxel and Monosialotetrahexosylganglioside in Anatomic Stage IV Breast Cancer AJCC v8, Chemotherapy-Induced Peripheral Neuropathy and Metastatic Breast Carcinoma, sponsored by Alliance for Clinical Trials in Oncology. Active, not recruiting at 33 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Alliance for Clinical Trials in Oncology · Phase 2, Interventional, and Supportive care

How we know

Updated Oct 19, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 96 studies in Breast Neoplasms by Alliance for Clinical Trials in Oncology — 5 open to participants now, 15 under way, 12 of them phase 3. Breast Neoplasms · Alliance for Clinical Trials in Oncology.

Enrollment
73rd of 77
7 · median 201
Started
2023
with 2 others
Phase 2
32 of 96
none open now
Primary completion
2026-11
later than 4 of 14 live
Registered
93rd of 96
by date

Among the 96 studies in Breast Neoplasms by Alliance for Clinical Trials in Oncology, this one is the 73rd largest by enrollment of the 77 interventional ones that give a count, is one of 3 that started in 2023, is one of 32 in phase 2, reaches primary completion later than 4 of the 14 other live ones, and was the 93rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 96 studies in Breast Neoplasms by Alliance for Clinical Trials in Oncology are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Breast Neoplasms by Alliance for Clinical Trials in Oncology, or all of them as a file.
02

Study summary

This early phase/phase II trial tests the safety, side effects, and best dose of monosialotetrahexosylganglioside (GM1) and whether it works in reducing or preventing chemotherapy-induced peripheral neuropathy (CIPN) in patients with breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) who are receiving treatment with paclitaxel. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Exposure to chemotherapy drugs like paclitaxel may cause a side effect called CIPN, which is a condition of weakness, numbness, and pain from nerve damage (usually in the hands and feet). GM1 is a part of the body's natural system that insulates nerves and helps to protect nerves from damage. Giving GM1 may help reduce or prevent CIPN in breast cancer patients receiving treatment with paclitaxel.

Read the detailed description

PRIMARY OBJECTIVES:

I. To obtain data to further support the safety of increasing monosialotetrahexosylganglioside (GM1) doses when given on day 1, concomitantly with paclitaxel. (Early phase) II. To evaluate the preliminary efficacy of GM1 compared with placebo at preventing paclitaxel-induced peripheral neuropathy sensory symptoms as measured by the six individual Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20 (QLQ-CIPN20) questions that quantify numbness (N), tingling (T), and pain in the fingers/hands and toes/feet. (Phase II)

SECONDARY OBJECTIVES:

I. To obtain additional data to support the safety of GM1 in the treated population. (Phase II) II. To obtain data to support that GM1 looks promising for preventing/decreasing acute paclitaxel pain syndrome as measured by the Acute Pain Syndrome Questionnaire. (Phase II)

EXPLORATORY OBJECTIVES:

I. Conduct of this clinical trial provides the opportunity to facilitate the better understanding of the natural history of paclitaxel-induced neuropathy, akin to what is being examined in a currently active trial, S1714. (Phase II) II. This clinical trial also provides an opportunity to conduct correlative studies to understand the mechanism of CIPN and/or identify biomarkers of CIPN or GM1 efficacy. (Phase II) III. To obtain efficacy data to assess the impact of GM1 on the anti-tumor activity of paclitaxel as evaluated by progression-free survival and overall survival. (Phase II)

OUTLINE: This is an early phase dose-escalation study of GM1 followed by a phase II study.

EARLY PHASE: Patients receive GM1 intravenously (IV) over 1 hour either once every 7 days, or once every 7 days for 3 doses followed by one week off, prior to paclitaxel administration.

PHASE II: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive GM1 IV 1 hour prior to paclitaxel administration and paclitaxel IV weekly for 12 weeks or 3 weeks on/1 week off for 12 doses.

ARM II: Patients receive placebo IV 1 hour prior to paclitaxel administration and paclitaxel IV weekly for 12 weeks or 3 weeks on/1 week off for 12 doses.

03

Conditions studied

  • Anatomic Stage IV Breast Cancer AJCC v8
  • Chemotherapy-Induced Peripheral Neuropathy
  • Metastatic Breast Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documentation of disease: Histologic diagnosis of breast cancer in women or men
  • Prior treatment- No previous exposure to GM1
  • Planned administration of paclitaxel, either given weekly, or weekly 3 weeks on/1 week off, to patients with metastatic cancer at a dose of 80 mg/m\^2
  • No planned treatment with concurrent immunotherapy
  • Score of 1 (none) and/or 2 (a little) on the six individual European Organization for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire (QLQ)- chemotherapy-induced peripheral neuropathy (CIPN)20 questions that quantify numbness (N), tingling (T), and pain in the fingers/hands and toes/feet (Items #31-36)
  • No diagnosis of fibromyalgia
  • No history of significant respiratory tract infection and/or infectious diarrhea within 14 days before registration
  • No history of stroke or cerebrovascular accident in the past 6 months prior to registration
  • No history of diagnosed neurologic or psychiatric disorders, including epilepsy or dementia
  • For women of , not pregnant and not nursing, because this study involves an agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown.

Therefore, for women of childbearing potential, a negative pregnancy test done =\< 7 days prior to registration is required. Of note, a female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)

  • Ability to complete questionnaires by themselves or with assistance
  • In order to complete the mandatory patient-completed measures, participants must be able to speak and/or read English and/or Spanish
  • Persons with impaired decision making such that they cannot understand the benefits or risks of trial participation, per the judgement of the consenting clinician, will not be eligible
  • Age >= 18 years
  • (ECOG) performance status 0-2
  • (ANC) >= 1,000/mm\^3
  • count >= 100,000/mm\^3
  • Creatinine =\< 1.5 x (ULN)
  • (AST) or alanine aminotransferase (ALT) =\< 2.5 x upper limit of normal (ULN)
  • Total =\< 1.5 x ULN
  • No planned use of duloxetine
  • No planned use of cryotherapy, compression therapy, or cryocompression therapy at study entry

Exclusion criteria

Exclusion Criteria:

  • N/A
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Arm I (paclitaxel, GM1)

    Patients receive GM1 IV 1 hour prior to paclitaxel administration and paclitaxel IV weekly for 12 weeks or 3 weeks on/1 week off for 12 doses.

    Drug: Paclitaxel · Drug: Monosialotetrahexosylganglioside · Other: Questionnaire Administration · Other: Quality-of-life assessment

  • Placebo comparator
    Arm II (paclitaxel, placebo)

    Patients receive placebo IV 1 hour prior to paclitaxel administration and paclitaxel IV weekly for 12 weeks or 3 weeks on/1 week off for 12 doses.

    Drug: Paclitaxel · Other: Questionnaire Administration · Other: Quality-of-life assessment · Drug: Placebo Administration

Interventions

  • Given IV

    Also known as: Anzatax, Asotax, Bristaxol

  • Given IV

    Also known as: Ganglioside GM-1, GM-1, GM1, Monosialoanglioside GM1

  • OtherQuestionnaire Administration

    Ancillary Studies

  • OtherQuality-of-life assessment

    Ancillary Studies

  • DrugPlacebo Administration

    Given IV

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (Early phase)

    Defined as the highest dose level that induces dose-limiting toxicity in less than one-third of patients (less than 1 out of 3 or less than 2 out of a maximum of 6 new patients).The constellation of adverse events as scored using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, version (v) 5.0 (CTCAE v5.0) will be summarized by reporting the number and percentage of patients. Specifically, the number and severity of all adverse events (overall and by dose-level) will be tabulated and summarized. The grade 3+ adverse events will also be described and summarized in a similar fashion. Further, all adverse events will be listed by system organ class and preferred term.

    Time frame: 6-7 months

  2. Composite response (Phase II)

    Reflects sensory paclitaxel-induced peripheral neuropathy symptom severity and onset. Measured using 6 individual Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20 (QLQ-CIPN20) questions that quantify numbness (N), tingling (T) and pain in the fingers/hands and toes/feet. Will calculate the highest (worst) N, T, and pain sensory score obtained anytime during paclitaxel exposure. Response is defined as a patient reporting a highest score of =\< 2 without discontinuing the study due to sensory paclitaxel-induced peripheral neuropathy. Chi-squared test will be used. Will report the proportion of patients achieving a composite response in each arm as well as the difference in proportions along with the 90% confidence interval. Will report the estimated odds ratio (monosialotetrahexosylganglioside \[GM1\]/placebo) and the corresponding 90% confidence interval for the true, but unknown odds ratio. Multiple logistic regression will be used to estimate the intervention

    Time frame: Up to one year

Secondary outcomes

  1. Percentage of patients who received full planned dose of paclitaxel

    Binary endpoint (yes or no). will graphically look at the percentages of patients receiving full planned paclitaxel doses per cycle within each arm. This is an indirect measure of paclitaxel-induced peripheral neuropathy, as most patients who stop receiving full dose paclitaxel do so because of paclitaxel-induced peripheral neuropathy troubles. In addition to graphically displaying the percentage of patients who receive full dose paclitaxel at each cycle, and according to arm, will make a between-arm comparison in terms of changes in the probability of receiving full dose paclitaxel over the 12 cycles of treatment. For latter analysis, the generalized estimating equations approach will be applied, with inference based on the empirical or sandwich variance estimator.

    Time frame: up to 1 year

  2. • Sensory subscale of the European Organization of Research and Treatment of Cancer (EORTC) QLQ-CIPN20

    Serially measured. Item scores are totaled and linearly converted to a 0-100 point scale with higher scores representing fewer symptoms or better quality of life. Will use the area under the curve (AUC) to summarize the serially measured sensory subscale scores. Patients will be analyzed in the arms to which they were randomized. In order to adjust for the stratification factors, the AUC will be computed for the two arms based on estimated parameters from a repeated-measures (means) mixed model.

    Time frame: Up to 1 year

  3. Rate of grade 3+ Adverse Events

    The proportion of patients experiencing a grade 3+ adverse events or toxicities will be described for each treatment arm, and will also be compared between the arms using Fisher's exact tests. Additional summaries and test will be performed as needed.

    Time frame: Up to 1 year

  4. • Serially measured patient-reported outcome that best describes the patients' aches/pains at its worst in the last 24 hours

    Within each arm, the mean score at each time point will be plotted longitudinally for the endpoints measuring aches and pains at its worst. The functional form of the relationship between time and each of these three patient-reported acute neuropathy items is not known. Penalized splines, a smoothing technique which does not require strong assumptions concerning the functional form of the pattern of change in the mean response, will be applied to these longitudinal data. In the two-arm setting (GM1 vs placebo) time trends will be incorporated in a non-parametric fashion, thereby allowing the mean response to change in a highly non-linear, but not predetermined, way. The intervention effect will be incorporated in the model in a parametric fashion, thereby allowing a relatively simple, but powerful, test of the intervention effect on changes in the mean response over time.

    Time frame: In the preceding 24 hours

  5. Serially measured patient-reported outcome that best describes the patients' aches/pains at its least in the last 24 hours

    Within each arm, the mean score at each time point will be plotted longitudinally for the endpoints measuring aches and pains at its least. The functional form of the relationship between time and each of these three patient-reported acute neuropathy items is not known. Penalized splines, a smoothing technique which does not require strong assumptions concerning the functional form of the pattern of change in the mean response, will be applied to these longitudinal data. In the two-arm setting (GM1 vs placebo) time trends will be incorporated in a non-parametric fashion, thereby allowing the mean response to change in a highly non-linear, but not predetermined, way. The intervention effect will be incorporated in the model in a parametric fashion, thereby allowing a relatively simple, but powerful, test of the intervention effect on changes in the mean response over time.

    Time frame: in the preceding 24 hours

  6. • Serially measured patient-reported outcome that best describes the patients' aches/pains on the average in the last 24 hours

    Within each arm, the mean score at each time point will be plotted longitudinally for the endpoints measuring aches and pains on average. The functional form of the relationship between time and each of these three patient-reported acute neuropathy items is not known. Penalized splines, a smoothing technique which does not require strong assumptions concerning the functional form of the pattern of change in the mean response, will be applied to these longitudinal data. In the two-arm setting (GM1 vs placebo) time trends will be incorporated in a non-parametric fashion, thereby allowing the mean response to change in a highly non-linear, but not predetermined, way. The intervention effect will be incorporated in the model in a parametric fashion, thereby allowing a relatively simple, but powerful, test of the intervention effect on changes in the mean response over time.

    Time frame: in the preceding 24 hours

Other outcomes

  1. Progression free survival (PFS)

    Distributions of PFS times will be estimated using Kaplan-Meier methodology.

    Time frame: Up to 4 years after the end of GM1 treatment

  2. Overall survival (OS)

    Distributions of OS times will be estimated using Kaplan-Meier methodology.

    Time frame: Up to 4 years after the end of GM1 treatment

  3. Serially measured total score of the EORTC QLQ-CIPN20

    Will use the AUC to summarize the serially measured EORTC QLQ-CIPN20 scores. Patients will be analyzed in the arms to which they were randomized. In order to adjust for the stratification factors, the AUC will be computed for the two arms based on estimated parameters from a repeated-measures (means) mixed model.

    Time frame: On day 1 of each dose prior to GM1, monthly after the end of GM1, at 8, 12, 16, 20, and 24 months after last study treatment

  4. Patient-reported severity and interference of numbness or tingling in hands or feet

    As measured by the Patient Reported Outcomes version CTCAE (PRO-CTCAE). The maximum grade for each of these events will be recorded for each patient and frequency tables will be generated and presented according to treatment arm. The descriptive analysis of the PRO-CTCAE endpoints will be based on the safety population and analyzed according to the treatment actually received.

    Time frame: On day 1 of each dose prior to GM1, monthly after the end of GM1, at 8, 12, 16, 20, and 24 months after last study treatment

  5. Serially measured patient-reported aggregate scores

    Measured by the 11-item Functional Assessment of Cancer Therapy - Gynecologic Oncology Group-Neurotoxicity 4. Will tabulate all available serially measured PROs at each protocol defined time point and within each arm; furthermore, will graphically display the longitudinal PROs over time. Will compare and contrast the descriptive findings between these CIPN-measuring instruments in this trial and in the corresponding longitudinal data obtained in S1714. No inferential statistics will be generated. Further, these descriptive summaries will be used to better understand these instruments.

    Time frame: On day 1 of each dose prior to GM1, monthly after the end of GM1, at 8, 12, 16, 20, and 24 months after last study treatment

  6. Serially measured patient-reported total score

    Measured by the 5-item Patient Reported Outcomes Measurement Information System-Neuropathic Pain Quality scale. Will tabulate all available serially measured PROs at each protocol defined time point and within each arm; furthermore, will graphically display the longitudinal PROs over time. Will compare and contrast the descriptive findings between these CIPN-measuring instruments in this trial and in the corresponding longitudinal data obtained in S1714. No inferential statistics will be generated. Further, these descriptive summaries will be used to better understand these instruments.

    Time frame: On day 1 of each dose prior to GM1, monthly after the end of GM1, at 8, 12, 16, 20, and 24 months after last study treatment

07

Study locations

33 sites
08

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2026, 36 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 36 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Mar 2028 → Nov 2026 and completion Mar 2032 → Nov 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2023
First posted
Mar 2, 2023
StartActual
Nov 2, 2023
Primary completionEst.
Nov 15, 2026was Mar 2028
CompletionEst.
Nov 15, 2028was Mar 2032
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 15, 2028→Nov 15, 2026
Oct 19, 2026
Study completion
Mar 15, 2032→Nov 15, 2028
Oct 19, 2026
Title
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)
Oct 1, 2026
Show all 3 updates
  1. Oct 19, 2026
    Primary completion Mar 15, 2028→Nov 15, 2026
    Study completion Mar 15, 2032→Nov 15, 2028
  2. Oct 2, 2026
    Minor edits only
    + 1 other change: verification date
  3. Oct 1, 2026
    Title Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05751668
Responsible party
Sponsor
First posted
Mar 2, 2023
Start date
Nov 2, 2023
Primary completion
Nov 15, 2026 (estimated)
Completion
Nov 15, 2028 (estimated)
Last update
Oct 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Monosialotetrahexosylganglioside

Start the discussion